Reagentes e instrumentos para imunologia, biologia celular e biologia molecular.
 
> Normal or Transformed Ovary and Fallopian Tube Media w/o HCT (Ince FOMI) (Liquid)

Normal or Transformed Ovary and Fallopian Tube Media w/o HCT (Ince FOMI) (Liquid)

Imprimir Imprimir
Please log in

Referência 506388-01-500ml

Tamanho : 500ml

Marca : US Biological

Solicitar mais informações

Contactar o distribuidor local :


Telefone : +1 850 650 7790

506388-01 Normal or Transformed Ovary and Fallopian Tube Media w/o HCT (Ince FOMI) (Liquid)

Clone Type
Polyclonal
Shipping Temp
Blue Ice
Storage Temp
4°C Do Not Freeze/-20°C

Normal or Transformed Ovary and Fallopian Tube Media (Ince)||Suggested Usage:|NORMAL IMMORTALIZED OVARY CELL LINES|Immortalized with hTERT-pgp|OCE1 Ovarian Surface|OCE2 Ovarian Surface||TRANSFORMED OVARY CELL LINES|Transformed with hTERT-gfp + LT/st|OCLE1 Ovarian Surface|OCLE2 Ovarian Surface||TUMORIGENIC OVARY CELL LINES|Transformed with hTERT-gfp + LT/st + H-Ras|OCLER1 Ovarian Surface|OCLER2 Ovarian Surface||NORMAL IMMORTALIZED FALLOPIAN TUBE CELL LINES|Immortalized with hTERT-pgp|FNE1 Fallopian Non-ciliated|FNE2 Fallopian Non-ciliated||TRANSFORMED FALLOPIAN TUBE CELL LINES|Transformed with hTERT-gfp + LT/st|FNLE1 Fallopian Non-ciliated|FNLE2 Fallopian Non-ciliated||TUMORIGENIC FALLOPIAN TUBE CELL LINES|Transformed with hTERT-gfp + LT/st + H-Ras|FNLER1 Fallopian Non-ciliated|FNLER2 Fallopian Non-ciliated||Tan A. Ince, MD, PhD - Fighting Cancer by Keeping Cancer Cells Alive ...|https://www.scientia.global/tan-ince-md-phd-fighting-cancer-keeping-cancer-cells-alive/||Feb 12, 2017 - Professor Ince was a visiting clinical scientist at the Massachusetts Institute of Technology from 2000 to 2007, where he developed a new cell culture nutrient medium that is now widely used to grow human breast and ovary cells.||Customer supplied:|To be supplemented with 0-2% fetal bovine serum to media|To be supplemented with Calbiochem 227036 Cholera Toxin w/o azide, 25ng/ml to media.||Appearance:|Red, clear, complete||FOMI Bullet 1 Included (506388B, |Colorless): |Supplied as a liquid. Vortex, spin down and add whole vial to 506388. ||Storage (506388B):|Liquid is stable at 4°C.||FOMI Bullet 2 Included (506388C, |Pink): |Supplied as a liquid. Thaw, vortex, spin down and add whole vial to 506388.||Storage (506388C):|Liquid is stable at -20°C||Storage and Stability w/o supplements):|Store at 4°C. Do not freeze. Light sensitive, store in the dark. Stable for 6 months w/o supplements.||Storage and Stability |(w/ supplements):|Complete media with supplements is stable for 6 weeks at 4°C. Do Not Freeze. Light sensitive, store in the dark.||Storage (506388B):|Liquid is stable at 4°C.||Storage (506388C):|Liquid is stable at -20°C.||Country of Origin:|United States ||FOMI Bullet Included (506388B): |Supplied as a liquid. Thaw, vortex, spin down and add whole vial to 506388. ||Storage (506388B):|Vial is stable at -20°C. Once thawed and added to 506388, the complete media is stable for 6 weeks at 4°C when stored in the dark.||Important Note: |Cholera toxin is NOT included in the liquid media nor the bullet. Shipping regulations have made it increasingly difficult to ship. Please procure from your local supplier. Calbiochem 227036 Cholera Toxin w/o azide, 25ng/ml to media.||Licensed by TumorGenesisTM. Manufactured for research use by US Biological.

Applications
Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. ||Toxicity and Hazards: All products should be handled by qualified personnel only, trained in laboratory procedures.
References
1. Tan A. Ince, MD, PhD - Fighting Cancer by Keeping Cancer Cells Alive ...https://www.scientia.global/tan-ince-md-phd-fighting-cancer-keeping-cancer-cells-alive. 2. AE Witt, CW Lee, TI Lee, DI Azzam, B Wang, C Caslini, F Petrocca, J Grosso, M Jones, EB Cohick, AB Gropper, C Wahlestedt, AL Richardson, R Shiekhattar, RA Young and TA Ince, Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer, Oncogene, 2016. DOI: 10.1038/ onc.2016.337. 3. A Thakkar, B Wang, M Picon-Ruiz, P Buchwald and TA Ince, Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer, Breast Cancer Res. Treat., 2016, 157, 77–90. 4. TA Ince, AD Sousa, MA Jones, JC Harrell, ES Agoston, M Krohn, LM Selfors, W Liu, K Chen, M Yong, P Buchwald, B Wang, KS Hale, E Cohick, P Sergent, A Witt, Z Kozhekbaeva, S Gao, AT Agoston, MA Merritt, R Foster, BR Rueda, CP Crum, JS Brugge, GB Mills, Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours, Nat. Commun., 2015, 6, 7419. 5. S Santagata, A Thakkar, A Ergonul, B Wang, T Woo, R Hu, JC Harrell, G McNamara, M Schwede, AC Culhane, D Kindelberger, S Rodig, A Richardson, SJ Schnitt, RM Tamimi and TA Ince, Taxonomy of breast cancer based on normal cell phenotype predicts outcome, J. Clin. Invest., 2014, 124, 859–870.